- Home Page
- For Health Professionals
- Healthy Vaginal Flora
- Efficacy and Dosing:
- Dual Therapy
- Tolerability
- Tindamax® (tinidazole) Drug Facts:
- Order Tindamax® Samples and Literature
- Wholesaler Order Entry Numbers
- CDC STD Treatment Guidelines
- Patient Counseling Information
- Website References
- Prescribing Information
- For Patients
- About Tindamax® (tinidazole)
- Press/Media:
- Press Releases
- 7/31/2007 – New Study Finds Tindamax® To Be Effective, Well-Tolerated Treatment for Bacterial Vaginosis
- 5/24/2007 – FDA Approves Tindamax® for Bacterial Vaginosis
- 11/13/2006 – CDC Recommends Tindamax® for the Treatment of Trichomoniasis
- 8/17/2007 – Mission Pharmacal Submits Supplemental New Drug Application for Tindamax® (Tinidazole) as Treatment of Bacterial Vaginosis
- 5/9/2006 – Most Common Curable STD a Significant Public Health Concern When Untreated, May Contribute to Spread of HIV
- 5/8/2006 – Mission Pharmacal Completes Phase III Study of Tindamax® for the Treatment of Bacterial Vaginosis
- 4/20/2006 – Mission Pharmacal Acquires Tindamax®: Treatment for Trichomoniasis, Most Common Non-Viral Sexually Transmitted Disease
- News
- Fact Sheets
- Press Releases
- Legal/Privacy
- Report an Adverse Event
- Contact
- Tindamax.com Site Map
Important Safety Information
WARNING: POTENTIAL RISK FOR CARCINOGENICITY
Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Its use should be reserved for the conditions described in INDICATIONS AND USAGE.
Contraindications
- Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives
- First trimester of pregnancy
- Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose
Warnings and Precautions
- Seizures and neuropathy have been reported. Discontinue Tindamax if abnormal neurologic signs develop
- Vaginal candidiasis may develop with Tindamax and require treatment with an antifungal agent
- Use Tindamax with caution in patients with blood dyscrasias. Tindamax may produce transient leukopenia and neutropenia
Adverse Reactions
Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation. To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.
Please see full Prescribing Information
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
